AS

Amandeep Singh Kalsi

Active Director Director DIN 07946774
DIN 07946774 First appointment Mar 2018 Primary industry Trading
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Amandeep Singh Kalsi

Data last updated:

Amandeep Singh Kalsi is a Director at Limpid Pharma Private Limited (since 2018). The company operates in Trading.

DIN 07946774
Primary Designation Director
Industry Trading
First Appointment 01 Mar 2018
Oldest Company Age 8 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Limpid Pharma Private Limited U51909HR2018PTC072827
Director01 Mar 20182018Active

Board colleagues of Amandeep Singh Kalsi

NameDINCompanyDesignation
Abhijatya Singh06467846Limpid Pharma Private LimitedDirector
Ramesh Kumar08081751Limpid Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Limpid Pharma Private Limited
Premium access

Shareholding and investment profile for Amandeep Singh Kalsi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amandeep Singh Kalsi

Amandeep Singh Kalsi currently holds 1 directorship: Limpid Pharma Private Limited (Director, since 01 Mar 2018).

Amandeep Singh Kalsi was first appointed on 01 Mar 2018 as Director at Limpid Pharma Private Limited.

The current boards of Amandeep Singh Kalsi's companies include Abhijatya Singh (Limpid Pharma Private Limited), Ramesh Kumar (Limpid Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available